First Trust Advisors LP Trims Position in Henry Schein, Inc. $HSIC

First Trust Advisors LP trimmed its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 40.4% during the 1st quarter, Holdings Channel reports. The firm owned 142,666 shares of the company’s stock after selling 96,878 shares during the period. First Trust Advisors LP’s holdings in Henry Schein were worth $10,514,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Dimensional Fund Advisors LP boosted its holdings in Henry Schein by 2.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,873,004 shares of the company’s stock worth $211,734,000 after buying an additional 56,687 shares during the period. Parallel Advisors LLC increased its stake in Henry Schein by 12.7% in the 1st quarter. Parallel Advisors LLC now owns 1,314 shares of the company’s stock worth $97,000 after buying an additional 148 shares in the last quarter. SEB Asset Management AB bought a new stake in Henry Schein during the first quarter valued at about $2,276,000. Bessemer Group Inc. lifted its position in shares of Henry Schein by 9.8% in the first quarter. Bessemer Group Inc. now owns 6,990 shares of the company’s stock valued at $515,000 after acquiring an additional 626 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Henry Schein by 0.6% in the first quarter. Bank of New York Mellon Corp now owns 545,599 shares of the company’s stock valued at $40,211,000 after acquiring an additional 3,380 shares in the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Insider Transactions at Henry Schein

In other news, Director William K. Daniel acquired 10,000 shares of Henry Schein stock in a transaction on Monday, May 11th. The shares were acquired at an average price of $69.19 per share, with a total value of $691,900.00. Following the purchase, the director directly owned 20,000 shares in the company, valued at $1,383,800. The trade was a 100.00% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.89% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

HSIC has been the subject of several research analyst reports. Citigroup began coverage on Henry Schein in a research report on Wednesday, April 15th. They set a “buy” rating and a $100.00 target price for the company. BMO Capital Markets assumed coverage on Henry Schein in a report on Wednesday, July 8th. They issued a “market perform” rating and a $85.00 price target on the stock. Mizuho dropped their price target on Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. UBS Group reaffirmed a “neutral” rating and set a $89.00 price objective (up from $85.00) on shares of Henry Schein in a report on Tuesday. Finally, Morgan Stanley reiterated an “underweight” rating and set a $64.00 price objective (up from $61.00) on shares of Henry Schein in a research report on Friday, April 24th. Eight investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $89.36.

Henry Schein Trading Up 0.7%

Shares of Henry Schein stock opened at $85.75 on Friday. Henry Schein, Inc. has a twelve month low of $61.94 and a twelve month high of $89.34. The company has a quick ratio of 0.75, a current ratio of 1.36 and a debt-to-equity ratio of 0.59. The business has a 50-day moving average price of $82.19 and a 200-day moving average price of $78.28. The firm has a market cap of $9.77 billion, a price-to-earnings ratio of 25.91, a PEG ratio of 1.64 and a beta of 0.81.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, May 5th. The company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.12. The company had revenue of $3.37 billion for the quarter, compared to the consensus estimate of $3.34 billion. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The firm’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.15 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Equities research analysts anticipate that Henry Schein, Inc. will post 5.32 EPS for the current fiscal year.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.